Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma

PURPOSE: BRAF inhibitors are clinically active in patients with advanced BRAF(V600)-mutant melanoma, although acquired resistance remains common. Preclinical studies demonstrated that resistance could be overcome using concurrent treatment with the HSP90 inhibitor XL888. METHODS: Vemurafenib (960 mg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Eroglu, Zeynep, Chen, Y. Ann, Gibney, Geoffrey T., Weber, Jeffrey S., Kudchadkar, Ragini R., Khushalani, Nikhil I., Markowitz, Joseph, Brohl, Andrew S., Tetteh, Leticia F., Ramadan, Howida, Arnone, Gina, Li, Jiannong, Zhao, Xiuhua, Sharma, Ritin, Darville, Lancia N.F., Fang, Bin, Smalley, Inna, Messina, Jane L., Koomen, John M., Sondak, Vernon K., Smalley, Keiran S.M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6195480/
https://ncbi.nlm.nih.gov/pubmed/29674508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0565
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados